Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.'
This Collection aims to showcase cutting-edge research in identification, validation, and clinical application of biomarkers that hold promise for accurate cancer diagnosis, prognosis, and prediction of drug resistance. We welcome Correspondences that address this multifaceted role of biomarkers in guiding personalized treatment strategies, improving patient outcomes, and advancing our understanding of cancer biology. Please note that this Collection will not accept any study based on TCGA analyses without independent cohort validation.
Each Correspondence should start with “To the Editor”, include a maximum of 2 tables or figures, a maximum of 15 references and up to 1500 words in text. It should also have two subsections to better delineate the content, Abstract and Results/Discussion.
This Collection welcomes submission of Correspondence Articles only.
Image credit: © [M] freshidea / stock.adobe.com